



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,731	04/26/2005	Serge Auvin	427.095	6471
47888 7590 06/13/2008 HEDMAN & COSTIGAN P.C. 1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036				
EXAMINER				
HABTE, KAHISAY				
ART UNIT		PAPER NUMBER		
1624				
MAIL DATE		DELIVERY MODE		
06/13/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of Allowability**Application No.**

10/532,731

Applicant(s)

AUVIN ET AL.

Examiner

Kahsay T. Habte

Art Unit

1624

- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 06/04/2008.
2. ☒ The allowed claim(s) is/are 1-4.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Charles Muserlian on June 5, 2008. Enter the following:

Replace claims 3-4 in the claim set (06/04/2008) with

Claim 3 (previously presented) A compound of claim 1, wherein

- ❖ R^1 , R^2 , R^3 , R^5 and R^6 are independently selected from the group consisting of hydrogen alkyl and alkoxy;

--

- ❖ R^2 is hydrogen or methyl;
- ❖ W is -O- or -S-;
- ❖ X is -Y-CO- or -O-Y-CO-;
- ❖ $-(AA)_n-$ is an $-(AA^2)-(AA^1)-$ such that AA^1 is Leu and AA^2 is an amino acid chosen from the group consisting of natural amino acids, 3-methylvaline, norvaline, phenylglycine, vinylglycine and 2-aminobutyric acid;
- ❖ R is hydrogen,
or a salt thereof.

Art Unit: 1624

Claim 4 (previously presented)

A compound of claim 1 is selected from the

group consisting of:



- N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N¹ [(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylcarbonyl)-L-leucyl-L-leucyl-N¹ [(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylcarbonyl)glycyl-N¹ [(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylcarbonyl)leucyl-N¹ [(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N⁶ [(benzyloxy)carbonyl]-N²-(10H-phenothiazin-2-ylcarbonyl)lysyl-N¹ [(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- 1-(10H-phenothiazin-2-ylcarbonyl)-L-prolyl-N¹ [(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;

Art Unit: 1624

- N-[(10H-phenothiazin-2-ylcarbonyl)glycyl]-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-ylcarbonyl)leucyl]-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-alanyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-β-alanyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-D-valyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- 3-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-N²-{[(10H-phenothiazin-2-yloxy)acetyl]amino}butanoyl)-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-norvalyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-seryl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-threonyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-N²-[(2S)-2-[(10H-phenothiazin-2-yloxy)acetyl]amino]-2-phenylethanoyl)-L-leucinamide;
- N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-N²-[(2S)-2-[(10H-phenothiazin-2-yloxy)acetyl]amino]but-3-enoyl)-L-leucinamide;

Art Unit: 1624

- 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alanyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N⁶-(benzyloxy)carbonyl-N²-(10H-phenothiazin-2-ylcarbonyl)lysyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- 1-(10H-phenothiazin-2-ylcarbonyl)-L-prolyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylcarbonyl)leucyl-N¹-[(3S)-2-(acetyloxy) tetrahydrofuran-3-yl]-L-leucinamide;
- N²-(10H-phenothiazin-2-ylcarbonyl)lysyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylacetyl)-L-leucyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- O-(tert-butyl)-N-(10H-phenothiazin-2-ylacetyl)-L-seryl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylacetyl)-L-alanyl-3-cyclohexyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-alaninamide;
- N-(10H-phenothiazin-2-ylacetyl)-L-leucyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- O-(tert-butyl)-N-(10H-phenothiazin-2-ylacetyl)-L-seryl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10H-phenothiazin-2-ylacetyl)-L-alanyl-3-cyclohexyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-alaninamide;
- N-[3-(10H-phenothiazin-2-yl)propanoyl]-L-leucyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[3-(10H-phenothiazin-2-yl)propanoyl]-L-leucyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-leucyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;

Art Unit: 1624

- N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-valinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-3-cyclohexyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-alaninamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-N-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-phenylalaninamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-N²-isobutyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-glycinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-leucyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-alanyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-β-alanyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-glycyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-D-valyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- 3-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-L-valyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-N²-[(2S)-2-[(10H-phenothiazin-2-yloxy)acetyl]amino]butanonyl-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-norvalyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-seryl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;

Art Unit: 1624

- N-[(10H-phenothiazin-2-yloxy)acetyl]-1-threo-nyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
 - N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-N²-{(2S)-2-[(10H-phenothiazin-2-yloxy)acetyl]amino}-7-phenylethano-yl)-L-leucinamide;
 - N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-N²-{(2S)-2-[(10H-phenothiazin-2-yloxy)acetyl]amino)-hmt-3-enoyl)-L-leucinamide;
 - 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alan-yl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
 - N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N¹-{(3S)-2-hydroxytetrahydrofuran-3-yl]-L-valinamide;
 - N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-3-cyclohexyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-alaninamide;
 - N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N¹-{(3S)-2-hydroxytetrahydrofuran-3-yl]-L-phenylalaninamide;
 - N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-N¹-{(3S)-2-hydroxytetrahydrofuran-3-yl]-N²-isobutylglycinamide;
 - N-[2-methyl-2-(10H-phenothiazin-2-yloxy)propanoyl]glycyl-N¹-{(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
 - N-[2-methyl-2-(10H-phenothiazin-2-yloxy)propanoyl]glycyl-N¹-{(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
 - N-(10,11-dihydro-5H-dibenzo[b,f]azepin-3-ylcarbonyl)-L-leucyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
 - N-(10,11-dihydro-5H-dibenzo[b,f]azepin-3-ylcarbonyl)-L-leucyl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
 - N-[(S-acetyl-10,11-dihydro-5H-dibenzo[b,f]azepin-3-yl)carbonyl]-L-leucyl-N¹-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
 - 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alan-yl-N¹-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide; and
- or a salt thereof.

Conclusion

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Kahsay T. Habte/
Primary Examiner, Art Unit 1624

June 13, 2008

